Skip to main content

Table 1 Active ongoing or completed clinical trials on targeted agents for the cancer lipogenesis enzymes/pathways

From: Posttranslational control of lipogenesis in the tumor microenvironment

Drugs

Targeted protein

Cancer type

Function

ClinicalTrial. gov identifier

Status

TVB-2640

FASN

Advanced tumors

To inhibit FASN

NCT02223247

Completed

TVB-2640

FASN

Breast and colon cancer

To inhibit FASN

NCT03179904

Recruiting

CLA

FASN

Breast cancer

To inhibit FASN

NCT00908791

Completed

Statins

HMGCR

Solid tumors

To inhibit HMGCR

NCT02285738

Completed

Metformin

AMPK

Acute lymphoblastic leukemia

To activate AMPK

NCT03118128

Recruiting

Metformin

AMPK

Breast, endometrial, Prostate cancer

To activate AMPK

NCT01620593

Completed

Lapatinib

AMPK

Metastatic breast cancer

To activate AMPK

NCT01477060

Terminated

RGX-104

LXRs

Lung and endometrial cancer

To activate LXRs

NCT02922764

Recruiting

NRX194204

RXR

Non-small cell lung cancer

agonist of RXR

NCT01540071

Active

Bexarotene

RXR

Cutaneous T-cell lymphoma

To activate RXR

NCT01007448

recruiting

Pioglitazone

PPARa

Bladder cancer

agonist of PPARa

NCT01637935

Completed

TPST-1120

PPARa

Hepatocellular carcinoma

antagonist of PPARα

NCT03829436

Active